Princess Marina Hospital IDCC
Gaborone, Botswana
Location status: Recruiting
NCT Number: NCT05807867
The study goal is to promote viral load suppression among women with serious mental illness (SMI) and HIV in Botswana, given that these women are especially vulnerable to psychiatric medication nonadherence and symptom exacerbation, which are made worse by stigma and threaten antiretroviral therapy (ART) adherence.
The investigators propose to test an intervention to reduce stigma due to the statuses of SMI and HIV, against an attention control condition, in the high-risk transition period after discharge from an initial psychiatric hospitalization. Specifically, the investigators are conducting a two-arm randomized controlled trial (RCT) with a 4-month follow-up to compare the effectiveness of 1) What Matters Most (WMM)-based intersectional stigma intervention delivered as clients transition from psychiatric hospitalization to outpatient care; and 2) an attention placebo control condition that follows a similar format to isolate the effects of the intervention.
The investigators will also assess policymaker workshops where peer women with SMI and HIV co-lead the reporting of RCT findings via lived experience to policymakers to initiate structural change.
Enabling women with SMI and HIV to resist stigma has the potential to improve their HIV outcomes and empower these women to elicit broader, structural-level change.
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Not applicable
Gaborone, Botswana
Location status: Recruiting
The proposed project, "RCT of an intersectional stigma intervention to sustain viral suppression among women living with serious mental illness and HIV in Botswana," will test a culturally tailored stigma intervention among women with co-occurring serious mental illness (SMI) and HIV receiving inpatient treatment at Sbrana Psychiatric Hospital in Lobatse, Botswana, who are then discharged into outpatient care. The culturally tailored stigma intervention is based on our novel 'what matters most' (WMM) approach to target intersectional stigma. The investigators will also be conducting a family-level stigma intervention to test its efficacy at reducing family-level SMI and HIV stigma, and to test family-level stigma as a mechanism for change in VL among women. Lastly, the investigators will pilot a policymaker workshop intended to facilitate structural-level change.
Populations included in the study:
RESEARCH AIM 2.
The investigators propose a two-arm randomized controlled trial (RCT) with a 4-month follow-up to compare the effectiveness of our WMM-based stigma intervention to reduce viral load (VL) at 4-month follow-up (primary outcome) and improve the secondary outcomes of antiretroviral treatment (ART) and psychiatric treatment adherence, MH outcomes (e.g., depression), and social outcomes (e.g., social integration).
In Botswana, families are usually contacted and engaged in psychiatric treatment planning during inpatient stay or on admission. The involvement of family continues during outpatient follow-ups since most patients are accompanied by some relative or caregiver on such visits. Because family acceptance can bolster achieving the capabilities of 'good womanhood' (i.e., by being a family caregiver), family members will receive a parallel, group stigma intervention, which could further facilitate treatment adherence of the recently discharged family member. Therefore, the investigators will conduct a parallel two-arm intervention among women's family members to test its effectiveness in reducing family-level stigma and to assess family-level stigma as a mechanism of change for primary and secondary outcomes among women with SMI and HIV (e.g., VL, ART and psychiatric treatment adherence, MH outcomes and Social outcomes).
Participants in Research Aim 2 will be 75% female identified (100% of inpatient participants will be female-identified, and the investigators are accounting for a 50-50 gender split among recruited family members). Estimated distribution is 270 women, 90 men.
RESEARCH AIM 3.
The investigators further propose to pilot and evaluate policymaker workshops whereby peer women with SMI and HIV share RCT findings via lived experience to policymakers to initiate structural-level change.
The investigators anticipate that the multisectoral stakeholder committee members (n=15) and policymakers (n=50) in Research Aim 3 will have ~50-50 gender split - 32 women, 33 men.
OVERVIEW.
UBotswana will recruit participants and conduct the intervention, assessments, and data management. Overseen by PI Yang, NYU will provide study oversight, expertise in WMM and stigma, and conduct data analyses; UPenn will provide expertise in integration of the intervention for SMI and HIV; Botswana-UPenn Partnership will provide expertise in integration of peers into stigma interventions and implementation of community based interventions in Botswana; UCSF and UC Riverside will offer expertise and supervision in stigma interventions.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
(A) WOMEN WITH SMI AND HIV
At Sbrana Psychiatric Hospital, the investigators will recruit women with SMI and HIV who are receiving treatment at that facility. Women with SMI and HIV will be receiving psychiatric care and ART and must:
The investigators will also recruit 6 to 8 women with SMI and HIV as peer co-leaders to facilitate the intervention. For women who are peer co-leaders, inclusion criteria include #1 to #7 above in addition to:
(B) FAMILY MEMBERS OF WOMEN WITH SMI AND HIV.
In Botswana, families are usually contacted and engaged in psychiatric treatment planning during inpatient stay or on admission. The involvement of family continues during outpatient follow-ups since most patients are accompanied by some relative or caregiver on such visits. Eligible participants include:
(C) POLICY MAKERS AND OTHER STAKEHOLDERS.
Policy makers will be
Intervention components consist of:
Note: "enhancing skills for discrimination" sessions for women and family members are provided when female participants transition to outpatient care, thus enabling practice of skills in community-based situations. Intervention closes with a ceremony intended to convey WMM by bestowal of ceremonial shawls. The family member version will follow the same format, but each component will be covered in one session (3 sessions total).
To isolate intervention effects, our attention control is designed to mimic all salient features of the WMM-based intervention (i.e., group format, co-leaders, duration, inpatient followed by community location) except for the WMM stigma content.
Time frame: Changes from baseline at 4 months after intervention completion (approximately 16 months from baseline)
Time frame: Changes from baseline at 4 months after intervention completion (approximately 16 months from baseline)
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) PRIME screen: psychosis,12 items
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) CES-D: depressive symptoms, 20 items
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) GAD-7: Anxiety symptoms, 7 items
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) PCL-5: trauma symptoms, 20 items
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) ISEL: social support, 4x 10 item subscales eg. belonging
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) Social integration scale: community integration, 10 items
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) EQ5D: health related quality of life, 5 items
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Medical records) : Refill monitoring via pharmacy records
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) AACTG Adherence Instrument: AACTG Adherence instrument, 3 items
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(EHR) : facility-records of HIV visits
Time frame: Changes from baseline at 4 months after intervention completion (approximately 16 months from baseline)
(Self-report) Kalichman HIV Stigma Scale: Internalized stigma e.g. HIV disclosure; 6 items
Time frame: Changes from baseline at 4 months after intervention completion (approximately 16 months from baseline)
(Self-report) Berger HIV Stigma Scale: perceived community stigma, anticipated stigma, enacted stigma; 27 items
Time frame: Changes from baseline at 4 months after intervention completion (approximately 16 months from baseline)
(Self-report) Internalized stigma of mental illness scale: 3 subscales (a) discrimination experience 5 items, (b) alienation 6 items, (c) social withdrawal 6 items
Time frame: Changes from baseline at 4 months after intervention completion (approximately 16 months from baseline)
(Self-report) Gender-Equitable Scale: attitudes towards gender norms e.g. sexuality; 4 subscales, 24 items
Time frame: Changes from baseline at 4 months after intervention completion (approximately 16 months from baseline)
(Self-report) WMM Womanhood + HIV: Culture Shapes, Culture Protects subscales; 20 items
Time frame: Changes from baseline at 4 months after intervention completion (approximately 16 months from baseline)
(Self-report) WMM Womanhood + SMI: Scale items to be developed in Aim 1
Time frame: Changes from baseline at 4 months after intervention completion (approximately 16 months from baseline)
(Self-report) Devaluation of families scale: family members' experience of SMI stigma, 7 items
Time frame: Changes from baseline at 4 months after intervention completion (approximately 16 months from baseline)
(Self-report) Courtesy Stigma Scale: family members' experience of HIV stigma; 9 items
Time frame: Changes from baseline at 4 months after intervention completion (approximately 16 months from baseline)
(Self-report) Gender-Equitable Scale: attitudes towards gender norms e.g. sexuality; 4 subscales, 24 items
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) distance to clinic; when ART initiated; side effect profile; 3 items
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) distance to clinic; visits to spiritual/traditional healers (Y/N and # of visits)
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) Beck Cognitive Insight Scale: illness insight; 15 items
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) psychiatric medication side effects
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) HIV Risk-Taking Behavior Scale: sexual risk behaviors; 11 items
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) Woman Abuse Screening: IPV; 8 items
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) Marlowe-Crowne Social Desirability Scale: 13 items
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) Zarit Burden Interview: family burden: subjective; 22 items
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) Causal Model Questionnaire for Schizophrenia: 6 subscales assessing explanatory model for SMI
Time frame: Baseline
(Self-report) : age; education; employment; income; marital status; urban/rural residence; living with family; maternal status; # of children; religiosity/religious affiliation
Time frame: Baseline
(Self-report) : onset age of psychiatric symptoms; duration of psychiatric illness; first psychiatric tx contact; diagnosis (psychotic/bipolar/severe depression); first diagnosis of HIV; first HIV treatment
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) AUDIT: alcohol use, 10 items
Time frame: Changes from baseline to intervention completion (an average of 12 months), and to 4 months (or 16 months from baseline) after intervention completion
(Self-report) DUDIT: substance use, used with AUDIT, 11 items
Time frame: Baseline
(Self-report) : Age; gender; education; income/employment; relationship to patient; religiosity/religious affiliation; HIV status; previous psych diagnosis
Contact information is provided by the study sponsor or research team.
Ari Ho-Foster, MPH
CONTACT
Lawrence Yang, PHD
CONTACT
New York University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05660148
Acquired Immunodeficiency Syndrome, Behavior
Amiens, France
View Trial DetailsNCT06900829
Acquired Immunodeficiency Syndrome, Behavior
Ghent, Belgium
View Trial DetailsNCT06141408
Acquired Immunodeficiency Syndrome, Behavior
Fairfax, Virginia, United States
View Trial DetailsNCT06463886
Acquired Immunodeficiency Syndrome, Behavior
Miami, Florida, United States
View Trial Details